S-8 1 d196947ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on August 5, 2021

Registration No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

UroGen Pharma Ltd.

(Exact name of registrant as specified in its charter)

 

 

 

State of Israel   98-1460746

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

400 Alexander Park Drive, 4th Floor, Princeton, New Jersey   08540
(Address of Principal Executive Offices)   (Zip Code)

2017 Equity Incentive Plan

(Full titles of the plans)

UroGen Pharma Ltd.

Molly Henderson

Chief Financial Officer

400 Alexander Park Drive, 4th Floor

Princeton, New Jersey 08540

Telephone: +1 (646) 768-9780

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

Charles J. Bair

Cooley LLP

4401 Eastgate Mall

San Diego, California 92121

+1 (858) 550-6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of securities

to be registered

  

Amount

to be

registered(1)

  

Proposed

maximum

offering price

per share(2)

  

Proposed

maximum

aggregate

offering price(2)

  

Amount of

registration fee

2017 Equity Incentive Plan

Ordinary Shares, par value NIS 0.01 per share

   400,000 shares(3)   $15.46   $6,184,000.00   $674.67

 

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional Ordinary Shares of the Registrant (“Ordinary Shares”) that become issuable under the UroGen Pharma Ltd. 2017 Equity Incentive Plan (the “Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction.

(2)

This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee, and is based on the average of the high and low sale prices per Ordinary Share as reported by The Nasdaq Global Market on August 2, 2021.

(3)

Represents the Ordinary Shares added to the shares authorized for issuance under the Plan pursuant to an amendment to the Plan approved by the Registrant’s shareholders at the Registrant’s 2021 Annual Meeting of Shareholders.

 

 

 

 

INCORPORATION BY REFERENCE

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective. The Registrant previously registered its Ordinary Shares for issuance under the Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on June 27, 2017 (File No. 333-218992), February 9, 2018 (File No.  333-222955), October 12, 2018 (File No.  333-227812) and August 10, 2020 (File No. 333-243750). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

 

ITEM 8.

EXHIBITS.

 

Exhibit
Number

   

Description

4.1    Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Report on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2017).
5.1    Opinion of Erdinast, Ben Nathan, Toledano & Co. with Hamburger Evron, Israeli counsel to the Registrant, as to the validity of the Registrant’s Ordinary Shares.
23.1    Consent of Independent Registered Public Accounting Firm.
23.2    Consent of Independent Registered Public Accounting Firm.
23.3    Consent of Erdinast, Ben Nathan, Toledano & Co. with Hamburger Evron. Reference is made to Exhibit 5.1.
24.1    Powers of Attorney. Reference is made to the signature page hereto.
99.1    UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 8, 2021).

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey, on August 5, 2021.

 

UROGEN PHARMA LTD.
By:  

/s/ Elizabeth Barrett

  Elizabeth Barrett
  President and Chief Executive Officer

POWERS OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Elizabeth Barrett and Molly Henderson, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

   

Title

   

Date

/s/ Elizabeth Barrett

Elizabeth Barrett

   

President, Chief Executive Officer and

Member of the Board of Directors

(Principal Executive Officer)

    August 5, 2021

/s/ Molly Henderson

Molly Henderson

   

Chief Financial Officer

(Principal Financial and Accounting Officer)

    August 5, 2021

/s/ Arie Belldegrun, M.D.

Arie Belldegrun, M.D.

    Chairman of the Board of Directors    August 5, 2021

/s/ Cynthia Butitta

Cynthia Butitta

    Member of the Board of Directors    August 5, 2021

/s/ Fred E. Cohen

Fred E. Cohen

    Member of the Board of Directors    August 5, 2021

/s/ Kathryn Falberg

Kathryn Falberg

    Member of the Board of Directors    August 5, 2021

/s/ Stuart Holden

Stuart Holden

    Member of the Board of Directors    August 5, 2021

/s/ Ran Nussbaum

Ran Nussbaum

    Member of the Board of Directors    August 5, 2021

/s/ Shawn C. Tomasello

Shawn C. Tomasello

    Member of the Board of Directors    August 5, 2021